Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
About Umicore Powering the cars of today and tomorrow. Reducing harmful emissions. Giving unique properties to high-end applications. Giving new life to used metals. As a global advanced materials and recycling group, we develop, produce, and
Overall Function: The Institutional Partnerships Officer will be part of the Institutional Partnerships team within EDF’s Global Development Department, which works to secure transformative support for EDF’s Mission. Reporting to the Senior Institutional Partnerships Officer, the